Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib

• Fernando Lopez-Rios ,

  * E-mail: flopezrios@hospitaldemadrid.com

  Affiliation Laboratorio de Dianas Terapéuticas, Hospital Universitario Sanchinarro, Madrid, Spain

  ⨯
• Barbara Angulo,

  Affiliation Laboratorio de Dianas Terapéuticas, Hospital Universitario Sanchinarro, Madrid, Spain

  ⨯
• Belen Gomez,

  Affiliation The Royal Marsden NHS Trust and The Institute of Cancer Research, Sutton, London, United Kingdom

  ⨯
• Debbie Mair,

  Affiliation The Royal Marsden NHS Trust and The Institute of Cancer Research, Sutton, London, United Kingdom

  ⨯
• Rebeca Martinez,

  Affiliation Laboratorio de Dianas Terapéuticas, Hospital Universitario Sanchinarro, Madrid, Spain

  ⨯
• Esther Conde,

  Affiliation Laboratorio de Dianas Terapéuticas, Hospital Universitario Sanchinarro, Madrid, Spain

  ⨯
• Felice Shieh,

  Affiliation Roche Molecular Systems, Pleasanton, California, United States of America

  ⨯
• Jeffrey Vaks,

  Affiliation Roche Molecular Systems, Pleasanton, California, United States of America

  ⨯
• Rachel Langland,

  Affiliation Roche Molecular Systems, Pleasanton, California, United States of America

  ⨯
• H. Jeffrey Lawrence,

  Affiliation Roche Molecular Systems, Pleasanton, California, United States of America

  ⨯
• David Gonzalez de Castro

  Affiliation The Royal Marsden NHS Trust and The Institute of Cancer Research, Sutton, London, United Kingdom

  ⨯